Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 1
2015 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

3 results
Results by year
Filters applied: . Clear all
Page 1
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ; PaTH Study Investigators. Black DM, et al. N Engl J Med. 2003 Sep 25;349(13):1207-15. doi: 10.1056/NEJMoa031975. Epub 2003 Sep 20. N Engl J Med. 2003. PMID: 14500804 Free article. Clinical Trial.
Factor VIII gene variants and inhibitor risk in African American hemophilia A patients.
Gunasekera D, Ettinger RA, Nakaya Fletcher S, James EA, Liu M, Barrett JC, Withycombe J, Matthews DC, Epstein MS, Hughes RJ, Pratt KP; Personalized Approaches to Therapies for Hemophilia (PATH) Study Investigators. Gunasekera D, et al. Blood. 2015 Aug 13;126(7):895-904. doi: 10.1182/blood-2014-09-599365. Epub 2015 Jan 23. Blood. 2015. PMID: 25617427 Free PMC article.
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis.
Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ; PaTH Study Investigators. Black DM, et al. N Engl J Med. 2005 Aug 11;353(6):555-65. doi: 10.1056/NEJMoa050336. N Engl J Med. 2005. PMID: 16093464 Free article. Clinical Trial.
Feedback